Research output per year
Research output per year
-
Ex vivo drug screening on patient-derived tumor material to advance functional precision in oncology: an overview on current approaches and unresolved challenges
Spiró, Z., El-Heliebi, A., Mair, M. J., Pieber, T. R., Prietl, B., Spiegl-Kreinecker, S., Stanzer, S., Wöhrer, A., Preusser, M. & Berghoff, A. S., Feb 2026, In: Cancer Treatment Reviews. 143, 103072.Research output: Contribution to journal › Review article › peer-review
Open Access -
Association of Intergenic and Intragenic MGMT Enhancer Methylation with MGMT Promoter Methylation, MGMT Protein Expression and Clinical and Demographic Parameters in Glioblastoma
Pühringer, K., Czarda, P., Iluca, S., Zappe, K., Weis, S., Spiegl-Kreinecker, S. & Cichna-Markl, M., 04 Apr 2025, In: International Journal of Molecular Sciences. 26, 7, 26 p., 3390.Research output: Contribution to journal › Article › peer-review
Open Access -
Personalized targeted glioblastoma therapies by ex vivo drug screening: Study protocol of the Advanced brain Tumor TheRApy Clinical Trial (ATTRACT)
Berghoff, A. S., Mair, M., Spiró, Z., Abdel Malak, C., El-Heliebi, A., Eckert, F., Furtner, J., König, F., Leibetseder, A., Nowosielski, M., Oberndorfer, S., Prietl, B., Pichler, J., Pieber, T. R., Spiegl-Kreinecker, S., Urbanic Purkart, T., Wöhrer, A., Widhalm, G., Preusser, M. & ATTRACT study group, 01 Jan 2025, In: Neuro-Oncology Advances. 7, 1, 9 p., vdaf056.Research output: Contribution to journal › Article › peer-review
Open Access -
Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens
Laemmerer, A., Lehmann, C. W., Mayr, L. & Spiegl-Kreinecker, S., Nov 2024, In: Neuro-Oncology. 27, 3, p. 811-827 17 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Myeloid cells coordinately induce glioma cell-intrinsic and cell-extrinsic pathways for chemoresistance via GP130 signaling
Cheng, J., Li, M., Motta, E., Barci, D., Song, W., Zhou, D., Li, G., Zhu, S., Yang, A., Vaillant, B. D., Imhof, A., Forné, I., Spiegl-Kreinecker, S., Zhang, N., Katayama, H., Bhat, K. P. L., Flüh, C., Kälin, R. & Glass, R., 20 Aug 2024, In: Cell Reports Medicine. 5, 8, 28 p., 101658.Research output: Contribution to journal › Article › peer-review
Open Access
-
Reconstructing the Cerebrovascular Microenvironment: A Human Cell Model of cVSMC–ECM Interaction
Gollwitzer, M. (Co-PI), Gruber, A. (Researcher), Hild, S. (Researcher), Spiegl-Kreinecker, S. (PI), Weis, S. (Researcher) & Roschger, C. (Researcher)
01.06.2026 → 31.05.2028
Project: Funded research › Other mainly public funds
-
ATTRACT side project: Molecular factors influencing PDC cultivation
Spiegl-Kreinecker, S. (Researcher) & Berghoff, A. S. (Researcher)
01.10.2024 → 31.12.2028
Project: Funded research › Other sponsors
-
Tumorsezernierte Signale als chemo-attraktive Faktoren für Gliom-invadierende Zellen und deren Rolle als immuntherapeutisches Angriffsziel
Spiegl-Kreinecker, S. (Researcher), Kälin, R. (Researcher) & Pitigala-Motal, L. (Researcher)
01.09.2024 → 31.08.2028
Project: Clinical studies › Clinical Study (Academic - no third-party funds)
-
ATTRACT
Rauch, P.-R. (Researcher), Spiegl-Kreinecker, S. (Researcher), Wurm, K. (Researcher) & Berghoff, A. S. (PI)
01.07.2024 → 31.12.2028
Project: Clinical studies › Clinical Study (Funded research)
-
Identifying metabolic targets for personalised medicine in glioma patients
Schreiner, L. (Researcher) & Spiegl-Kreinecker, S. (Researcher)
01.01.2020 → 31.12.2026
Project: Clinical studies › Clinical Study (Academic - no third-party funds)
-
AMPK inhibition synergistically enhances the effect of fatostatin-treatment in glioblastoma cell models
Spiegl-Kreinecker, S. (Speaker)
2025Activity: Talk or presentation › Poster presentation › science-to-science
-
Translationale Forschung bei Hirntumoren
Spiegl-Kreinecker, S. (Speaker) & Gruber, A. (Speaker)
06 May 2019Activity: Talk or presentation › Invited talk › science-to-science